CAPR Capricor Therapeutics, Inc. gains 44% Jan 27, 2021

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.http://www.priceseries.com/trade/CAPR-Capricor-Therapeutics-Inc-stock-gains-44-percent-a-Trade-Record-by-priceSeries-2021010720210127.html